TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28933745
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (160 mg/day for six weeks)
Study: 24244261
Drug: lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide plus cetuximab combination therapy
Study: 24244261
Drug: lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenalidomide 25 mg/day monotherapy
Study: 12656878
Drug: Oral surgeon
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral surgeon
Study: 12656878
Drug: Oral surgeon
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral surgeon (total time including unscheduled visits)
Study: 14733634
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (HDCP) 100 mg/m2
Study: 14733634
Drug: Moderate-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose cisplatin (MDCP) 50 mg/m2 combined with ifosfamide (3 g/m2) and mitomycin (6 mg/m2)
Study: 14733634
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (HDCP)
Study: 14733634
Drug: Moderate-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose cisplatin (MDCP)
Study: 8960474
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Study: 8960474
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Study: 11020403
Drug: Trabeculectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy and Ahmed implant
Study: 31744345
Drug: CML-enriched maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CML-enriched maternal milk formulation (8 mg GA per day)
Study: 31744345
Drug: Control maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control maternal milk formulation (4 mg GA per day)
Study: 30992195
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) and Saxagliptin (2.5 mg)
Study: 28101379
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 18 months in daily practice
Study: 28101379
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 18 months in RCT
Study: 20865876
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Study: 20865876
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Study: 8375267
Drug: Bovine NPH
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine NPH insulin
Study: 26383996
Drug: Treatment change
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment change candidates at week 12
Study: 26383996
Drug: Treatment change
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment change candidates at week 24
Study: 17456913
Drug: 20% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% azelaic acid gel
Study: 15868618
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant relaxin treatment
Study: 12537345
Drug: GCB (Gluma
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCB (Gluma Comfort Bond) with rescue treatment using Gluma Desensitizer
Study: 9708388
Drug: Intrasheath injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasheath injection
Study: 9708388
Drug: Mixed sheath
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed sheath and subcutaneous injection
Study: 18683898
Drug: Binge eating
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binge eating disorder pharmacotherapy trials (specific interventions not detailed in the abstract)
Study: 18683898
Drug: Exclusionary psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusionary psychotropic medication
Study: 15627931
Drug: Palpebral hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpebral hygiene solution used for 3 days
Study: 15627931
Drug: Palpebral hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpebral hygiene solution used for 4 days
Study: 15627931
Drug: Palpebral hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpebral hygiene solution used for 5 days
Study: 15627931
Drug: Palpebral hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpebral hygiene solution used for 6 days
Study: 1098580
Drug: Matched control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched control (no heparin)
Study: 28609389
Drug: Conjugated estrogens/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens/MPA 1.5 mg
Study: 26416102
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10(4) PfSPZ in 50 μL/2 doses
Study: 26416102
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10(4) PfSPZ in 10 μL/2 doses
Study: 26416102
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 10(4) PfSPZ in 10 μL/8 doses
Study: 26416102
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 10(4) PfSPZ in eight 10 μL injections
Study: 16045458
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg cotrimoxazole (CTX)
Study: 16045458
Drug: 960 mg
Normalized name: glycerin 960 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg cotrimoxazole (CTX)
Study: 2210587
Drug: Buscopan plus
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan plus (hyoscine‐N‐butylbromide 30 mg/day + paracetamol 1500 mg/day)
Study: 2210587
Drug: Buscopan (hyoscine‐N‐butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan (hyoscine‐N‐butylbromide 30 mg/day)
Study: 2210587
Drug: Paracetamol (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1500 mg/day)
Study: 6786132
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 130 ml/kg . min
Study: 6786132
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 100 ml/kg . min
Study: 6786132
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 70 ml/kg . min
Study: 28759431
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid Extracellular Matrix and Compression Therapy
Study: 26721139
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (75 mg voltaren tablet orally every day for four days)
Study: 21859991
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 250 mg, twice per day, continuously for 36 weeks
Study: 21859991
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 250 mg
Study: 17356040
Drug: Intravenous antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antioxidant therapy (n-acetylcysteine, selenium, vitamin C)
Study: 12930177
Drug: Concurrent resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent resistance and endurance training (C, n = 9)
Study: 8657760
Drug: Corticosteroid medication
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid medication
Study: 6439090
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (3 mg)
Study: 26897125
Drug: Hazelnuts (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnuts (42 g)
Study: 26897125
Drug: Chocolate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate (50 g)
Study: 26897125
Drug: Potato crisps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato crisps (50 g)
Study: 25652757
Drug: Stanozolol 2
Normalized name: stanozolol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol 2 mg twice daily
Study: 22699838
Drug: PEG-P (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-P (1.5 g/kg divided twice per day for 2 days)
Study: 22699838
Drug: Senna (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna (15 mL daily for ages 6-12 or 30 mL daily for ages 12-21 for 2 days)
Study: 21362056
Drug: Concurrent strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent strength and endurance (SE) training
Study: 19563006
Drug: Perioperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative administration of celecoxib (200 mg twice daily, starting 3 days before TKA and extending to 5 days postoperatively)
Study: 19563006
Drug: Perioperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative administration of celecoxib
Study: 19563006
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (postoperative administration of celecoxib, 200 mg twice daily, starting 2 hours after TKA and extending to 5 days postoperatively)
Study: 15546434
Drug: Low-fat plant
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat plant sterol ester (PSE)‐enriched spread (21 g day(‐1))
Study: 11342469
Drug: Magnetic Resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic Resonance (MR) using gadolinium-diethylenetriamine pentaacetic acid bismethylamide (Omniscan; 0.1 mmol/kg injected at 3 mL/s IV) during hyperemia (dipyridamole 0.56 mg/kg)
Study: 9246252
Drug: Treatment focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment focusing on sexual dysfunction
Study: 9246252
Drug: Treatment focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment focusing on interpersonal problems
Study: 9246252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both sexual dysfunction and interpersonal problems
Study: 3518552
Drug: Protocol I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol I (0 mg fentanyl)
Study: 3518552
Drug: Protocol II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol II (0.05 mg fentanyl)
Study: 3518552
Drug: Protocol III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol III (0.1 mg fentanyl)
Study: 3518552
Drug: Protocol IV
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol IV (0.15 mg fentanyl)
Study: 24630745
Drug: Interdisciplinary occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary occupational and sport therapy intervention for dementia patients suffering from apathy, provided once a week for 10 months.
Study: 12652617
Drug: all-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all-trans-retinoic acid (ATRA) at a dosage of 25 mg/m(2)/day
Study: 10853849
Drug: 1,250 mg
Normalized name: garlic 1,250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,250 mg azithromycin
Study: 1991527
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive (OC, 7‐7‐7)
Study: 1991527
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to monophasic pill (1/35)
Study: 1991527
Drug: 0.5/35 monophasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5/35 monophasic pill
Study: 1991527
Drug: 1/35 monophasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/35 monophasic pill
Study: 6826814
Drug: Cephalexin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (twice daily)
Study: 6826814
Drug: Dicloxacillin (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin (four times daily)
Study: 26818376
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (one stick of sugarless gum during the pause interval of drinking polyethylene glycol solution)
Study: 26818376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drank polyethylene glycol solution according to the general protocol)
Study: 25066331
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg per day tapered) and fludrocortisone (50 μg tablet once per day)
Study: 23202523
Drug: HAI-05 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI-05 vaccine (15, 45, and 90 µg) with Alhydrogel® (0.75 mg aluminum per dose)
Study: 23202523
Drug: HAI-05 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI-05 vaccine (90 µg) without Alhydrogel®
Study: 20214068
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Estazolam
Study: 12404512
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid (CSF) from MS patients with 0.1 mM ITU (specific iNOS inhibitor)
Study: 12404512
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid (CSF) from MS patients with 1 mM L-NMMA (nonisoform specific NOS inhibitor)
Study: 354826
Drug: L-alpha-methyldopa hydrazine
Normalized name: L-alpha-Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-alpha-methyldopa hydrazine
Study: 31340316
Drug: Strength program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength program with TheraBands® for 12 weeks, with two weekly sessions
Study: 22981376
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (2 hours weekly for six months)
Study: 22981376
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (control for patients)
Study: 12943436
Drug: Active infant
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active infant orthopedic treatment with Latham dentomaxillary alignment (DMA) appliance inserted at 5 to 6 weeks of age.
Study: 12943436
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active infant orthopedic treatment (nonorthopedic group).
Study: 11711509
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg per day)
Study: 11711509
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg per day)
Study: 9164679
Drug: Primary medical
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary medical therapy (PMT)
Study: 18230798
Drug: Adjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoendocrine therapy
Study: 8047746
Drug: Surrogate information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surrogate information time for monitoring treatment effects
Study: 3310870
Drug: alpha‐2a interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐2a interferon at 30 X 10(6) IU/ml
Study: 3310870
Drug: alpha‐2a interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐2a interferon at 10 X 10(6) IU/ml
Study: 2100737
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aqueous extract (Group A)
Study: 2100737
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg standardized extract (Group C)
Study: 25543971
Drug: Diltiazem 360
Normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 360 mg/day (or 5 mg/kg/day)
Study: 23953594
Drug: 200 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/day of vitamin K1
Study: 17374063
Drug: Topical high-potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical high-potency corticosteroid before UVB exposure
Study: 12638566
Drug: Rocuronium 1
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1 mg x kg(‐1)
Study: 12638566
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg x kg(‐1)
Study: 1796130
Drug: Methylphenidate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.5 mg/kg infusion
Study: 1796130
Drug: Neuroleptics (on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptics (on treatment)
Study: 1796130
Drug: Neuroleptics (off
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptics (off treatment)
Study: 29167092
Drug: Dry needling,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling, manual therapy, and exercise
Study: 29167092
Drug: Sham dry
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham dry needling, manual therapy, and exercise
Study: 31825525
Drug: Abdominal paracentesis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal paracentesis and intraperitoneal infusion of catumaxomab
Study: 31825525
Drug: Catumaxomab infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catumaxomab infusion
Study: 28650782
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt containing Lactobacillus acidophilus ATCC 4356 and Bifidobacterium bifidum ATCC 29521 (200 g daily)
Study: 28650782
Drug: Xylitol-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol-containing chewing gums (two gums three times daily after each meal; total xylitol content: 5.58 g daily)
Study: 19635898
Drug: Tafenoquine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 200 mg weekly for 6 months
Study: 31087729
Drug: Single-use negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-use negative pressure wound therapy (s-NPWT)
Study: 31087729
Drug: Traditional negative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional negative pressure wound therapy (t-NPWT)
Study: 30266270
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus plantarum P8 (10 log CFU daily)
Study: 28470492
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (30 mL for 90 days)
Study: 28470492
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (30 mL for 90 days)
Study: 28470492
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (30 mL for 90 days)
Study: 12917744
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g caffeine
Study: 9443520
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg, p.o.
Study: 9443520
Drug: Cyclobenzaprine 5
Normalized name: cyclobenzaprine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg, p.o.
Study: 8440100
Drug: Continuous modes
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous modes of renal replacement therapy (CAVH/CAVHD)
Study: 27650406
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 20‐70 mg/day, n=25
Study: 24018777
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment at 1-month interval
Study: 24018777
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment at 3-month interval
Study: 24018777
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment intervals (1-month and 3-month)
Study: 16809072
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as allocated (specific intervention details not available)
Study: 10996870
Drug: Regimen IR
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen IR (isoniazid 300 mg daily and rifampin 600 mg daily)
Study: 10996870
Drug: Regimen I
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I (isoniazid 300 mg daily for 12 months)
Study: 28535785
Drug: Targeted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted medication therapy management (MTM) intervention
Study: 8419602
Drug: Nebulized racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized racemic epinephrine, 0.1 ml/kg
Study: 8419602
Drug: Nebulized salbutamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized salbutamol, 0.03 ml/kg
Study: 20157180
Drug: Ocrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 200 mg/m2 (n=15)